Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence - Takeaways - MDSpire

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

  • By

  • Zeng-Yi Huang

  • Jialiang Chen

  • Boman Zhu

  • Xiao-Lian Liu

  • April 30, 2026

  • 0 min

Share

  • 1

    Teclistamab, a BCMA × CD3 bispecific antibody, is effective for relapsed/refractory multiple myeloma but increases infection risk due to hypogammaglobulinemia.

  • 2

    The pooled incidence of any-grade infections in patients treated with teclistamab is 56.5%, while grade ≥3 infections occur in 27.6% of cases.

  • 3

    In clinical trials, the risk of infections is significantly higher compared to real-world evidence, with any-grade infections at 76.4% versus 45.4%.

  • 4

    Infection-related mortality among teclistamab patients ranges from 0.9% to 7.3%, with COVID-19 and opportunistic pathogens being common.

  • 5

    Standardized infection surveillance and IgG monitoring are recommended to optimize safety in patients receiving teclistamab therapy.

Original Source(s)

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

  • by Zeng-Yi Huang, Jialiang Chen, Boman Zhu, Xiao-Lian Liu

  • April 30, 2026

Related Content

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

  • March 31, 2026

  • 2 min
Evaluating Hypoalbuminemia as a Prognostic Indicator in Monoclonal Gammopathy of Undetermined Significance (MGUS) within Its Biological Framework